logo

Advaxis Inc. (ADXS)



Trade ADXS now with
  Date
  Headline
1/7/2020 8:17:34 AM Advaxis Says FDA Cleared IND Application For Initiation Of Phase 1 Clinical Study Of ADXS-504
12/3/2019 8:07:48 AM Advaxis Reports Submission Of IND Application For ADXS-HOT Drug Candidate For Prostate Cancer
9/9/2019 8:17:00 AM Advaxis Q3 Loss/shr $1.00 Vs. Loss/shr $3.99 Prior Year
7/23/2019 8:35:21 AM Advaxis Announces Pricing Of $16 Mln Public Offering
7/15/2019 8:11:30 AM Advaxis Announces New Immune Data From ADXS-NEO Phase 1 Clinical Trial
6/10/2019 4:10:47 PM Advaxis Q2 Loss/share $1.59 Vs. Loss $4.03 Year Ago
5/15/2019 8:32:11 AM FDA Lifts Partial Clinical Hold On Phase 3 AIM2CERV Study Of Axalimogene Filolisbac
4/1/2019 8:10:41 AM Advaxis Announces Updated Data From Phase 1/2 KEYNOTE-046 Study
3/25/2019 8:14:47 AM Advaxis Granted U.S. Patent Relating To Axalimogene Filolisbac
2/14/2019 8:33:57 AM Advaxis Announces Enrollment Of First Patient In Its Phase 1/2 Trial For ADXS-HOT In Non-Small Cell Lung Cancer
9/11/2018 9:28:59 AM Advaxis Announces Closing Of Public Offering Of Common Stock And Warrants
9/10/2018 4:32:52 PM Advaxis Q3 Loss/share $0.27 Vs. Loss $0.80 Year Ago
9/7/2018 9:29:13 AM Advaxis Prices Public Offering Of 16.67 Mln Shares And Warrants To Purchase Up To 14.17 Mln Shares
7/30/2018 8:07:52 AM Advaxis Announces FDA Allowance Of IND Application For ADXS-HOT Drug Candidate For NSCLC
  
 
>